Clinical effect of paclitaxel albumin in neoadjuvant chemotherapy for advanced ovarian cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025940

Enrollment

Unknown

Registered

2019-09-15

Start date

2019-12-01

Completion date

Unknown

Last updated

2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced ovarian cancer

Interventions

1:Albumin Paclitaxel combined with carboplatin

2:Paclitaxel combined with Carboplatin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. First diagnosed ovarian cancer patients, and confirmed by cytology as cancer; 2. Ovarian/fallopian tube/peritoneal cancer stage III or IV was assessed by two or more gynecologic oncologists. 3. There are high risk factors for perioperative complications or the possibility of residual lesions less than 1 cm after cytoreductive surgery.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Tumor markers;ascites;imaging changes;	—

Countries

China

Contacts

Public ContactQiling Li

The First Affiliated Hospital of Xi'an Jiaotong University

liqilinglady@163.com+86 18991232838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026